CY1118923T1 - ΔΡΑΣΤΙΚΑ ΜΕΤΑΛΛΑΓΜΑΤΑ Fc ΑΝΤΙΣΩΜΑΤΟΣ ΑΝΘΕΚΤΙΚΑ ΣΕ ΠΡΩΤΕΑΣΕΣ - Google Patents

ΔΡΑΣΤΙΚΑ ΜΕΤΑΛΛΑΓΜΑΤΑ Fc ΑΝΤΙΣΩΜΑΤΟΣ ΑΝΘΕΚΤΙΚΑ ΣΕ ΠΡΩΤΕΑΣΕΣ

Info

Publication number
CY1118923T1
CY1118923T1 CY20171100444T CY171100444T CY1118923T1 CY 1118923 T1 CY1118923 T1 CY 1118923T1 CY 20171100444 T CY20171100444 T CY 20171100444T CY 171100444 T CY171100444 T CY 171100444T CY 1118923 T1 CY1118923 T1 CY 1118923T1
Authority
CY
Cyprus
Prior art keywords
mutal
mutuals
host
active protective
containing molecules
Prior art date
Application number
CY20171100444T
Other languages
English (en)
Inventor
William Strohl
Robert Jordan
Randall Brezski
Original Assignee
Janssen Biotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech, Inc. filed Critical Janssen Biotech, Inc.
Publication of CY1118923T1 publication Critical patent/CY1118923T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Μονοκλωνικό αντίσωμα και άλλα Fc-περιέχοντα μόρια μπορούν να κατασκευαστούν χρησιμοποιώντας τις αποκαλυπτόμενες παραλλαγές στην περιοχή Fc που προκαλούν αυξημένη αντίσταση σε πρωτεάσες του ξενιστή ή προερχόμενες από παθογόνα και εμφανίζουν την ικανότητα να αλληλεπιδρούν με υποδοχείς Fcγ και να πυροδοτούν κυτταροτοξικότητα κατευθυνόμενη από συμπλήρωμα όπως αποδεικνύεται σε λειτουργικούς προσδιορισμούς. Τα Fc-περιέχοντα μόρια είναι χρήσιμα στη θεραπευτική αγωγή διαφόρων νόσων και διαταραχών στις οποίες συμβάλλουν με τη δράση τους λειτουργίες του ξενιστή οδηγούμενες από Fcγ.
CY20171100444T 2010-12-23 2017-04-19 ΔΡΑΣΤΙΚΑ ΜΕΤΑΛΛΑΓΜΑΤΑ Fc ΑΝΤΙΣΩΜΑΤΟΣ ΑΝΘΕΚΤΙΚΑ ΣΕ ΠΡΩΤΕΑΣΕΣ CY1118923T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061426619P 2010-12-23 2010-12-23
US201161540882P 2011-09-29 2011-09-29
PCT/US2011/065174 WO2012087746A1 (en) 2010-12-23 2011-12-15 Active protease-resistant antibody fc mutants

Publications (1)

Publication Number Publication Date
CY1118923T1 true CY1118923T1 (el) 2018-01-10

Family

ID=46314374

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100444T CY1118923T1 (el) 2010-12-23 2017-04-19 ΔΡΑΣΤΙΚΑ ΜΕΤΑΛΛΑΓΜΑΤΑ Fc ΑΝΤΙΣΩΜΑΤΟΣ ΑΝΘΕΚΤΙΚΑ ΣΕ ΠΡΩΤΕΑΣΕΣ

Country Status (31)

Country Link
US (2) US8871204B2 (el)
EP (1) EP2654780B1 (el)
JP (1) JP6012624B2 (el)
KR (1) KR101900280B1 (el)
CN (1) CN103260640B (el)
AU (1) AU2011349719B2 (el)
BR (1) BR112013018317A2 (el)
CA (1) CA2822366A1 (el)
CO (1) CO6741179A2 (el)
CR (1) CR20130292A (el)
CY (1) CY1118923T1 (el)
DK (1) DK2654780T3 (el)
EA (1) EA028658B1 (el)
EC (1) ECSP13012712A (el)
ES (1) ES2623912T3 (el)
GT (1) GT201300167A (el)
HR (1) HRP20170595T1 (el)
HU (1) HUE033205T2 (el)
IL (1) IL226987A (el)
LT (1) LT2654780T (el)
MX (1) MX347077B (el)
MY (1) MY162489A (el)
NI (1) NI201300057A (el)
NZ (1) NZ612379A (el)
PL (1) PL2654780T3 (el)
PT (1) PT2654780T (el)
RS (1) RS55906B1 (el)
SG (1) SG191233A1 (el)
SI (1) SI2654780T1 (el)
WO (1) WO2012087746A1 (el)
ZA (1) ZA201305538B (el)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3153526T3 (da) 2008-01-31 2020-12-14 Inst Nat Sante Rech Med Antistoffer mod human cd39 og anvendelse deraf til inhibering af aktivitet af t-regulatoriske celler
US10053513B2 (en) * 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
DK2654780T3 (en) * 2010-12-23 2017-04-10 Janssen Biotech Inc ACTIVE PROTEASE-RESISTANT ANTIBODY-FC MUTANTS
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
PL2726092T3 (pl) 2011-06-28 2019-11-29 Inhibrx Lp Polipeptydy fuzyjne serpiny i sposoby ich stosowania
WO2013117647A1 (en) 2012-02-07 2013-08-15 Innate Pharma Mica binding agents
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
US10865243B2 (en) * 2014-07-16 2020-12-15 Hinrich Abken Chimeric antigen receptor and its use
CN104177496B (zh) * 2014-09-02 2015-03-11 安源生物科技(上海)有限公司 人IgG2抗体铰链区修饰体
CN106852149B (zh) 2014-10-10 2021-08-27 依奈特制药公司 Cd73阻断
WO2016131950A1 (en) 2015-02-20 2016-08-25 Innate Pharma Cd73 blockade
CN114316068A (zh) * 2014-10-27 2022-04-12 英伊布里克斯公司 丝氨酸蛋白酶抑制剂融合多肽和其使用方法
DK3221359T3 (da) 2014-11-17 2020-06-22 Regeneron Pharma Fremgangsmåder til tumorbehandling ved anvendelse af CD3XCD20-bispecifikt antistof
US10196445B1 (en) 2015-03-17 2019-02-05 Bristol-Myers Squibb Company Ipilimumab variant with enhanced ADCC
EP3277725B1 (en) 2015-03-30 2020-11-25 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
JP2018517708A (ja) 2015-06-05 2018-07-05 ニューヨーク・ユニバーシティ 抗ブドウ球菌生物学的薬剤のための組成物及び方法
JP6937737B2 (ja) * 2015-07-24 2021-09-22 グリックニック インコーポレイテッド 改良された補体結合を有する高次多量体化免疫グロブリンｆｃ組成物を作製するためのヒトタンパク質断片の融合タンパク質
CA2994825A1 (en) 2015-08-05 2017-02-09 Janssen Biotech, Inc. Anti-cd154 antibodies and methods of using them
WO2017059196A2 (en) 2015-09-30 2017-04-06 Janssen Biotech, Inc. Antagonistic antibodies specifically binding human cd40 and methods of use
WO2017064043A1 (en) 2015-10-12 2017-04-20 Innate Pharma Cd73 blocking agents
JP7033062B2 (ja) * 2015-10-23 2022-03-09 アポジェニックス アーゲー 一本鎖ｃｄ１３７受容体アゴニストタンパク質
WO2017157948A1 (en) 2016-03-14 2017-09-21 Innate Pharma Anti-cd39 antibodies
RU2018128215A (ru) 2016-03-15 2020-04-15 Иннейт Фарма Антитела против mica
KR102462084B1 (ko) * 2016-05-23 2022-11-02 모멘타 파머슈티컬스 인코포레이티드 유전자 조작 Fc 작제물에 관한 조성물 및 방법
CN107474136B (zh) * 2016-06-08 2023-03-07 上海交通大学医学院 增强激动型抗体活性的抗体重链恒定区序列
GB2552473A (en) * 2016-07-21 2018-01-31 Evox Therapeutics Ltd Surface decoration of extracellular vesicles
WO2018065552A1 (en) 2016-10-06 2018-04-12 Innate Pharma Anti-cd39 antibodies
EP3596124A1 (en) 2017-03-16 2020-01-22 Innate Pharma Compositions and methods for treating cancer
CN113603781B (zh) * 2017-03-28 2022-09-02 礼进生物医药科技（上海）有限公司 用于增强肿瘤微环境中免疫应答的治疗剂和方法
WO2018207023A2 (en) * 2017-05-10 2018-11-15 Albajuna Therapeutics, S.L. Fc-fusion protein derivatives with high dual hiv antiviral and immunomodulatory activity
PT3456736T (pt) 2017-09-19 2021-05-28 Tillotts Pharma Ag Variantes de anticorpos
MX2020012107A (es) 2018-06-18 2021-01-29 Innate Pharma Composiciones y procedimientos para el tratamiento del cancer.
AU2019331024A1 (en) 2018-08-31 2021-03-18 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for CD3/C20 bispecific antibodies
JP7479383B2 (ja) 2018-09-27 2024-05-08 エクシリオ デベロップメント， インコーポレイテッド マスクされたサイトカインポリペプチド
WO2020114616A1 (en) 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
EP3711772A1 (en) 2019-03-20 2020-09-23 Oslo Universitetssykehus HF Recombinant proteins and fusion proteins
GB201906685D0 (en) 2019-05-13 2019-06-26 Ultrahuman Six Ltd Activatable protein constructs and uses thereof
US20220380457A1 (en) * 2019-08-23 2022-12-01 City Of Hope Igg antibody compositions and methods of making the same
BR112023002123A2 (pt) * 2020-08-07 2023-03-07 Genentech Inc Proteína de fusão fc, ácidos nucleicos isolados, método de produção da proteína de fusão fc, formulação farmacêutica, métodos para expandir o número de células dendríticas (dcs) em um indivíduo e para tratar um câncer, proteína fc sem efetora e anticorpo
WO2022167729A1 (en) * 2021-02-04 2022-08-11 Helsingin Yliopisto A cross-hybrid fc-fusion polypeptide targeting pd-l1 and methods and uses related thereto
CN117597365A (zh) * 2021-05-04 2024-02-23 再生元制药公司 多特异性fgf21受体激动剂及其应用
WO2023109928A1 (zh) * 2021-12-16 2023-06-22 上海宝济药业有限公司 抗免疫球蛋白降解酶酶切的Fc变体

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
EP1082137A4 (en) 1998-05-06 2004-05-19 Univ Temple REVERSE OF PERCENTAL RESPONSE BY INTERRUPTING THE MACROPHAGE RECEPTOR FcSg (g) RI
PL209786B1 (pl) * 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
ES2420835T3 (es) 1999-04-09 2013-08-27 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de las moléculas inmunofuncionales
US7129331B2 (en) 2000-05-31 2006-10-31 Pestka Biomedical Laboratories, Inc. Phosphorylated polypeptides and uses related thereto
GB0130228D0 (en) 2001-12-18 2002-02-06 Hansa Medica Ab Protein
US8188231B2 (en) * 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
EP1833510A4 (en) 2004-12-27 2010-02-10 Progenics Pharmaceuticals Neva ORAL ADMINISTRATION ANTITOXIN ANTIBODIES AND METHODS OF MAKING AND USING THE SAME
US20070041979A1 (en) 2005-08-19 2007-02-22 Raju T S Proteolysis resistant antibody preparations
AU2006299429B2 (en) * 2005-10-03 2012-02-23 Xencor, Inc. Fc variants with optimized Fc receptor binding properties
PT2188306T (pt) * 2007-08-10 2016-09-13 Janssen Biotech Inc Fragmentos de clivagem de imunoglobulinas como indicadores de doença e composições para deteção e ligação relacionadas
KR102467302B1 (ko) 2007-09-26 2022-11-14 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
US20100260751A1 (en) 2007-09-28 2010-10-14 Raju T Shantha Methods and Structural Conformations of Antibody Preparations with Increased Resistance to Proteases
PT2211904T (pt) * 2007-10-19 2016-11-02 Seattle Genetics Inc Agentes de ligação a cd19 e seus usos
AU2010239216B2 (en) 2009-04-21 2012-07-12 Amgen Inc. Fragmentation resistant IgG1 Fc-conjugates
DK2654780T3 (en) * 2010-12-23 2017-04-10 Janssen Biotech Inc ACTIVE PROTEASE-RESISTANT ANTIBODY-FC MUTANTS
US8729985B2 (en) 2012-01-23 2014-05-20 Electro-Mechanical Corporation Switchgear visible disconnect mechanical interlock

Also Published As

Publication number Publication date
LT2654780T (lt) 2017-03-27
KR101900280B1 (ko) 2018-11-08
BR112013018317A2 (pt) 2017-03-21
CN103260640A (zh) 2013-08-21
MX2013007291A (es) 2013-09-13
EP2654780A4 (en) 2015-03-18
ES2623912T3 (es) 2017-07-12
HRP20170595T1 (hr) 2017-06-16
SG191233A1 (en) 2013-07-31
EP2654780B1 (en) 2017-02-01
CO6741179A2 (es) 2013-08-30
KR20140003485A (ko) 2014-01-09
EA201390958A1 (ru) 2013-11-29
US8871204B2 (en) 2014-10-28
JP6012624B2 (ja) 2016-10-25
HUE033205T2 (en) 2017-11-28
ZA201305538B (en) 2015-01-28
EP2654780A1 (en) 2013-10-30
MX347077B (es) 2017-04-10
NI201300057A (es) 2014-02-25
WO2012087746A1 (en) 2012-06-28
CN103260640B (zh) 2015-12-02
CR20130292A (es) 2013-10-03
IL226987A (en) 2017-07-31
JP2014504301A (ja) 2014-02-20
US9611328B2 (en) 2017-04-04
DK2654780T3 (en) 2017-04-10
EA028658B1 (ru) 2017-12-29
PL2654780T3 (pl) 2017-07-31
MY162489A (en) 2017-06-15
US20130011386A1 (en) 2013-01-10
ECSP13012712A (es) 2013-08-30
AU2011349719A1 (en) 2013-07-04
RS55906B1 (sr) 2017-09-29
CA2822366A1 (en) 2012-06-28
NZ612379A (en) 2014-10-31
PT2654780T (pt) 2017-04-06
AU2011349719B2 (en) 2016-09-15
GT201300167A (es) 2014-09-26
SI2654780T1 (sl) 2017-06-30
US20150139984A1 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
CY1118923T1 (el) ΔΡΑΣΤΙΚΑ ΜΕΤΑΛΛΑΓΜΑΤΑ Fc ΑΝΤΙΣΩΜΑΤΟΣ ΑΝΘΕΚΤΙΚΑ ΣΕ ΠΡΩΤΕΑΣΕΣ
CY1121204T1 (el) Συνθεσεις και μεθοδοι για τη θεραπευτικη αγωγη για διαταραχες που προκαλουνται απο την ige
CY1122816T1 (el) Στοχοθετημενοι συνδετικοι παραγοντες εναντι β7-η1
CY1121695T1 (el) Ενωσεις και συνθεσεις ως αναστολεις κινασης c-kit
CY1123028T1 (el) Σταθερα και διαλυτα αντισωματα που αναστελλουν τον vegf
CY1121327T1 (el) Τροποποιημενα αντισωματα anti-il-23p19
CY1120556T1 (el) Δικυκλικα ετεροκυκλα ως αναστολεις fgfr
CY2019008I1 (el) Χρηση τροποποιημενων απο χιμαιρικο αντιγονικο υποδοχεα τ κυτταρων στη θεραπευτικη αγωγη καρκινου
CY1117859T1 (el) Αντισωματα και ανοσοσυζευγματα anti-cd79b και μεθοδοι χρησης
EA201290413A1 (ru) МУТИРОВАННЫЕ Fc АНТИТЕЛ С УСТРАНЕННЫМИ ЭФФЕКТОРНЫМИ ФУНКЦИЯМИ
CY1119445T1 (el) Αντισωματα εναντι του ανθρωπινου gdf8
EA201500172A1 (ru) Модифицированные полипептиды фактора х и их применение
SMT201600398B (it) Inibitori di proteina chinasi (varianti), uso di questi nel trattamento di malattie oncologiche e composizione farmaceutica basata su questi
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
BR112015009942A2 (pt) derivados de tiofeno fundidos tricíclicos como inibidores de jak
BR112014019825A2 (pt) Glicoengenharia quimioenzimática de anticorpos e fragmentos fc dos mesmos
EA201101521A1 (ru) Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
DK3295957T3 (da) Anti il-17ra-antistofformulering og terapeutiske regimener til behandling af psoriasis
BR112013013781A2 (pt) anticorpos humanizados para liv-1 e uso dos mesmos para tratar câncer
EA201400875A1 (ru) Антитела к cd47 и способы их применения
EA201001372A1 (ru) Формы рифаксимина и их применение
CL2008000935A1 (es) Anticuerpo monoclonal humano anti-ige o fragmento del mismo; acido nucleico que lo codifica; vector y celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos relacionados con ige.
EA202090031A2 (ru) Человеческие антитела против gfr3 и способы их применения
UA111340C2 (uk) Антитіло, яке специфічно зв'язується з tnf-альфа людини
TN2015000276A1 (fr) Novel compounds